with data on survival as the criteria for evaluation , it has been shown that combined chemotherapy using doxorubicin plus cyclophosphamide achieves greater median survival for patients with squamous cell cancer of the lung than single-drug chemotherapy using cyclophosphamide , under the conditions of this study ;
C0050385
doxorubicin
C0010583
cyclophosphamide